Le Lézard
Classified in: Health, Science and technology
Subject: FDA

Optina Diagnostics Receives Breakthrough Device Designation from U.S. FDA for a Retinal Imaging Platform to Aid in the Diagnosis of Alzheimer's Disease

MONTREAL, May 8, 2019 /CNW Telbec/ - Optina Diagnostics announces today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to its retinal imaging platform (CAPRS1/MHRC2). Optina Diagnostics' platform uses Artificial Intelligence (AI) to analyze the data rich hyperspectral retinal images captured with the MHRC during a simple eye scan. Optina Diagnostics' platform is intended for the detection of likely positron-emission tomography (PET) amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. Optina Diagnostics' platform is an adjunct to other diagnostic evaluations.

Amyloid PET is the standard method for the detection of amyloid plaques in the brain, a key hallmark of Alzheimer's disease, and may be useful to confirm the diagnosis and optimize the patient management of patients being evaluated of Alzheimer's disease and other causes of cognitive decline. However, amyloid PET is an expensive technique of limited accessibility. In clinical practice, therefore, the diagnosis of Alzheimer's disease is mostly based on clinical symptoms, without evaluation of the amyloid status, which leads to incorrect diagnosis for nearly one third of the patients presenting at the memory clinic with cognitive impairment and half of those presenting with ambiguous cases.

Optina Diagnostics is working towards a non-invasive and more accessible means via a simple eye imaging test to improve the diagnosis accuracy and management of patients evaluated for Alzheimer's disease or other form of cognitive decline.

"We are excited to receive this Breakthrough Device Designation from the FDA as it recognizes the potential benefits the Optina Diagnostics' platform could bring to clinicians, their patients and families in the diagnosis of Alzheimer's disease and will permit to expedite its development and regulatory approval in the U.S." said David Lapointe, CEO of Optina Diagnostics. "Optina Diagnostics' technology based on data-rich hyperspectral retinal imaging combined with AI opens tremendous possibilities to have insights into the brain non-invasively and at a low cost. The Optina Diagnostics technology could also be helpful to accelerate and reduce the cost for the enrollment of participants that are really on the Alzheimer's path to conduct clinical trials for disease-modifying drugs for Alzheimer's disease."

The Breakthrough Device Program is a voluntary program for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversible debilitating diseases or conditions. This program is designed to expedite the development and review of these medical devices.

Alzheimer's disease is the most common type of dementia, which affects the ability to think, reason and remember clearly, and is the most frequent cause of institutionalization for long-term care. This progressive degenerative brain disease is ultimately fatal, as no disease-modifying treatment currently exits to delay its progression. Nowadays, more than 50 million people are diagnosed with Alzheimer's or a related dementia. It is listed as the sixth-leading cause of death in the United States. The prediction is that by 2050, the number of people suffering from Alzheimer's disease will triple, affecting 14 million people in the US alone, due to aging population demographics. Early detection of this disease is Optina Diagnostics' principal mission.

Optina Diagnostics is a Montreal-based company focused on the development of technology for the early detection of diseases through hyperspectral imaging of the retina. Optina Diagnostics brings an AI approach to biomarker detection with its first application in support to the early diagnosis of Alzheimer's disease. optinadx.com

1 CAPRS: Cerebral Amyloid Predictor Retina Scan
2 MHRC: Metabolic Hyperspectral Retinal Camera


SOURCE Optina Diagnostics

These press releases may also interest you

at 17:10
The report on the global sinus dilation devices market provides qualitative and quantitative analysis for the period from 2016 to 2024. Read the full report: https://www.reportlinker.com/p05751705/?utm_source=PRN The report predicts the global sinus...

at 17:05
The report on the global self-injections market provides qualitative and quantitative analysis for the period from 2016 to 2024. Read the full report: https://www.reportlinker.com/p05751706/?utm_source=PRN The report predicts the global...

at 17:00
Global Regenerative Medicine Market 2020-2024 The analyst has been monitoring the global regenerative medicine market and it is poised to grow by USD 9.55 bn during 2020-2024, progressing at a CAGR of 20% during the forecast period. Our reports on...

at 16:30
PTC Therapeutics, Inc. today announced that the Company will host a webcast conference call to report its fourth quarter and year-end 2019 financial results and provide an update on the company's business and outlook on Monday, March 2, 2020 at 4:30...

at 16:20
Global Medical Textiles Market 2020-2024 The analyst has been monitoring the global medical textiles market and it is poised to grow by USD 2.99 bn during 2020-2024, progressing at a CAGR of 5% during the forecast period. Our reports on global...

at 16:15
Working in conjunction with Israel's Minister of Health, Rabbi Yaakov Litzman and Moshe Bar Siman Tov, Dir. General of the Ministry of Health, Sheba Medical Center at Tel HaShomer will host those Israeli citizens who had been confined to the Diamond...

News published on 8 may 2019 at 12:14 and distributed by: